Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.55 |
| ▸ | STS | P08842 | 6/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22118487 | 0.90 | STS (0.48) | HSD11B1HTR2AGRM2STSPTPN2 | |
| SCHEMBL14655077 | 0.89 | KMT2A (0.56) | HSD11B1STSPTPN2PTPN1PTPN6 | |
| SCHEMBL5968515 | 0.88 | HSD11B1 (0.46) | HSD11B1HTR2AGRM2STSPTPN2 | |
| SCHEMBL2956024 | 0.87 | HSD11B1 (0.52) | HSD11B1HTR2AGRM2STSPTPN2 | |
| SCHEMBL4232496 | 0.84 | HSD11B1 (0.64) | HSD11B1HTR2AGRM2KMT2ALMNA | |
| SCHEMBL7620925 | 0.84 | HSD11B1 (0.44) | HSD11B1HTR2AGRM2STSPTPN2 | |
| SCHEMBL24510127 | 0.83 | ALDH1A1 (0.64) | HSD11B1KMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL29745265 | 0.80 | STS (0.53) | STSPTPN2PTPN1PTPN6MGLL | |
| SCHEMBL23214916 | 0.80 | STS (0.53) | STSPTPN2PTPN1PTPN6MGLL | |
| SCHEMBL7401499 | 0.80 | KDM1A (0.53) | KMT2AALDH1A1GPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066302-A1 | DEUTERATED FORMS AND DERIVATIVES OF VOLINANSERIN | TERRAN BIOSCIENCES INC. | 2025-02-27 | — | — | US | disclosed |
| US-20220106272-A1 | Deuterated Forms And Derivatives Of Volinanserin | TERRAN BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220106272-A1 | Deuterated Forms And Derivatives Of Volinanserin | TERRAN BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
| WO-2020132461-A1 | DEUTERATED FORMS AND DERIVATIVES OF VOLINANSERIN | CONCERT PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-1362589-B1 | Use of R(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol for the treatment of sleep disorders | AVENTIS PHARMA INC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1937265-A2 | COMINATION OF A HYPNOTIC AGENT AND R(+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1289527-B1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL OR ITS PRODRUG TO TREAT DEMENTIA OR COGNITIVE IMPAIRMENT | AVENTIS PHARMA INC (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-0796619-A1 | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders | MERRELL PHARMACEUTICALS INC. (US) | 1997-09-24 | — | — | EP | disclosed |
| US-5618824-A | ADMINISTERING N-ARALKYL PIPERIDINEMETHANOL DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0749309-A1 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDERS WITH 5-HT 2? ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5561144-A | TREATMENT OF SCHIZOPHRENIA | MERRELL PHARMACEUTICALS INC. (US) | 1996-10-01 | — | — | US | disclosed |
| WO-1995024194-A1 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDERS WITH 5-HT2 ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0531410-B1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | MERRELL DOW PHARMA (US) | 1994-11-30 | — | — | EP | disclosed |
| EP-0531410-A4 | (+)--G(A)-(2,3-DIMETHOXYPHENYL)-1- 2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | — | 1993-05-26 | — | — | EP | disclosed |
| EP-0531410-A1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL. | MERRELL DOW PHARMA (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5134149-A | Serotonin antagonist | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-28 | — | — | US | disclosed |
| WO-1991018602-A1 | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066302-A1 | DEUTERATED FORMS AND DERIVATIVES OF VOLINANSERIN | DRD2, HTR3A, COMT | HSD11B1 186/4885HTR2A 16/4885GRM2 848/4885 |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | CYP2E1, CYP1A1, ADRM1 | HSD11B1 728/4885HTR2A 1477/4885GRM2 781/4885 |
| US-20220106272-A1 | Deuterated Forms And Derivatives Of Volinanserin | DRD2, HTR3A, COMT | HSD11B1 186/4885HTR2A 16/4885GRM2 848/4885 |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | HCRTR2, OPRD1, HCRTR1 | HSD11B1 405/4885HTR2A 47/4885GRM2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.